phrykt

Verrica Pharmaceuticals Inc. (VRCA): who owns it and who trades it

As of Nov 16, 2026, VRCA insiders reported 12 purchases worth $18.2M in the last 12 months. The largest buyer was Paul B Manning (Director), with $17.5M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Verrica Pharmaceuticals

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VRCA

43 funds and institutions reported VRCA shares worth $28.5M at the end of Q2 2026, about 27% of the company. The largest holder is Caligan Partners LP with 5.4%.

Funds and institutions (13F) 27%Everyone else 73%

10 largest owners, by share of the company

Caligan Partners LP5.4%
Cannell Capital LLC4.6%
Affinity Asset Advisors, LLC4.1%
Velan Capital Investment Management LP2.7%
Armistice Capital, LLC2.5%
Boothbay Fund Management, LLC1.6%
Vanguard Capital Management LLC1.6%
Mariner, LLC1.2%
Geode Capital Management, LLC0.8%
BlackRock, Inc.0.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Caligan Partners LP923,9105.38%$5.7MNo change
Cannell Capital LLC783,9234.56%$4.8M+14%
Affinity Asset Advisors, LLC707,3384.12%$4.3MNo change
Velan Capital Investment Management LP471,5592.75%$2.9MNo change
Armistice Capital, LLC426,3042.48%$2.6M-18%
Boothbay Fund Management, LLC280,7341.63%$1.7MNo change
Vanguard Capital Management LLC279,3101.63%$1.7M+48%
Mariner, LLC207,2301.21%$1.3M+744%
Geode Capital Management, LLC138,1600.80%$846K-1%
BlackRock, Inc.74,3440.43%$455K+93%
Vanguard Fiduciary Trust Co70,1730.41%$429K+8%
Two Sigma Investments, LP40,8250.24%$250K-19%
State Street Corp28,9160.17%$177KNo change
Northern Trust Corp26,9960.16%$165K-15%
DAFNA Capital Management LLC23,7500.14%$145K-85%
Jane Street Group, LLC23,6540.14%$145K-52%
Verdad Advisers, LP23,0690.13%$141K+91%
Renaissance Technologies LLC21,7690.13%$133K-33%
Legacy Trust16,5840.10%$101K-4%
Fifth Third Bancorp14,0000.08%$85.7KNew

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VRCA insiders reported $18.2M of open-market purchases and $0 of sales.

Purchases, 12 months
$18.2M
12 trades, 5 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 18, 2026
Filed Aug 18, 2026

Purchases and sales by month

$211K$211KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 18, 2026Noah L. RosenbergCMOPurchase2,030$4.92$10KForm 4
Aug 18, 2026John J. KirbyCFOPurchase5,000$4.93$24.6KForm 4
Aug 17, 2026Noah L. RosenbergCMOPurchase4,200$4.91$20.6KForm 4
Aug 17, 2026David ZawitzChief Operating OfficerPurchase6,000$4.98$29.9KForm 4
Aug 17, 2026Jayson RiegerCEOPurchase5,000$4.91$24.6KForm 4
Aug 14, 2026Jayson RiegerCEOPurchase20,000$5.06$101KForm 4
Nov 25, 2025Noah L. RosenbergCMOPurchase2,357$4.24$10KForm 4
Nov 25, 2025John J. KirbyCFOPurchase3,536$4.24$15KForm 4
Nov 25, 2025David ZawitzChief Operating OfficerPurchase10,000$4.24$42.4KForm 4
Nov 25, 2025Jayson RiegerCEOPurchase94,311$4.24$400KForm 4
Nov 25, 2025Paul B ManningDirectorPurchase1.38M$4.24$5.8MForm 4
Nov 25, 2025Paul B ManningDirectorPurchase2.75M$4.24$11.7MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Paul B ManningDirector, 10% owner$17.5M–Nov 25, 2025
Jayson RiegerCEO and President, Director$526K–Aug 17, 2026
David ZawitzChief Operating Officer$72.3K–Aug 17, 2026
Noah L. RosenbergCMO$40.6K–Aug 18, 2026
John J. KirbyInterim CFO$39.6K–Aug 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VRCA short interest

Low short interest. 1.4% of VRCA shares are sold short: about 1 share in 70. Over the last 12 reports the number of shares short went down 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 244,405 VRCA shares were sold short, 1.4% of the shares outstanding, up 26.9% from the report before. At the average daily volume of 53,391 shares, buying them all back would take about 4.6 trading days (days to cover).

Shares short, % of all shares

1.42%May 15Oct 302.59%

Days to cover

4.6May 15Oct 3012.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026244,4051.42%+27%53,3914.6
Oct 15, 2026192,6131.12%-2%50,1093.8
Sep 30, 2026196,2211.14%-3%48,2844.1
Sep 15, 2026202,7551.18%-9%48,5254.2
Aug 31, 2026222,5721.30%-17%156,7211.4
Aug 14, 2026269,3491.57%-6%52,1775.2
Jul 31, 2026287,7471.68%-9%29,2369.8
Jul 15, 2026315,7601.84%-3%28,52911.1
Jun 30, 2026324,6791.89%-8%51,5456.3
Jun 15, 2026351,8182.05%-7%37,9859.3
May 29, 2026379,2782.21%-8%40,5709.3
May 15, 2026412,4802.40%-29%115,9493.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Verrica Pharmaceuticals company events

Verrica Pharmaceuticals filed 6 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Aug 6, 2026.

  1. Aug 6, 2026ResultsReleased financial results. Filing
  2. Jun 9, 2026LeadershipAs described in Item 5.07 below, on June 5, 2026, at the 2026 Annual Meeting of Stockholders of Verrica Pharmaceuticals Inc., the Company’s stockholders approved the Verrica Pharmaceuticals, Inc. Amended and Restated 2018 Equity Incentive Plan. Filing
  3. May 12, 2026ResultsReleased financial results. Filing
  4. Mar 11, 2026ResultsReleased financial results. Filing
  5. Dec 30, 2025LeadershipThe Board of Directors of Verrica Pharmaceuticals Inc. appointed Charles Frantzreb to serve as a director of the Company effective immediately. Filing
  6. Nov 24, 2025AgreementVerrica Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with certain institutional investors and a Securities Purchase Agreement with other accredited investors (together with the Institutional Investor Purchase Agreement, the “ Purchase Agreements ” and the investors under the… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Verrica Pharmaceuticals financials

Famous investors that hold VRCA

2 of the 50 well-known investors we track reported holding VRCA in their latest 13F filing. The largest position is Ken Griffin's, worth $187K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202639,002$187K0.0%New
Jim Simons · Renaissance TechnologiesQ3 202631,884$153K0.0%+46%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VRCA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Dellora Investments LP13G5.2%
Nov 16, 2026Dellora Investments LP13G5.2%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A5.0%
Nov 13, 2026Affinity Asset Advisors, LLC13G/A5.0%

Questions about Verrica Pharmaceuticals Inc. (VRCA) stock

Who owns the most VRCA stock?

The largest reported owner of Verrica Pharmaceuticals Inc. (VRCA) is Caligan Partners LP, with 5.4% of the company. In total, 43 funds and institutions reported holding VRCA at the end of Q2 2026, together about 27% of the shares. See the largest owners.

Are VRCA insiders buying or selling?

In the last 12 months, VRCA insiders reported 12 open-market purchases worth $18.2M and no sales. The latest trade was on Aug 18, 2026. See every trade.

What is the short interest in VRCA?

As of Oct 30, 2026, 244,405 VRCA shares were sold short, 1.4% of the shares outstanding, up 26.9% from the report before. At the average daily volume of 53,391 shares, buying them all back would take about 4.6 trading days (days to cover). See the history.

Which famous investors hold VRCA?

2 of the 50 well-known investors we track reported VRCA in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $187K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.